Å·²©ÌåÓýƽ̨

Medical biotechnology companies focus on developing innovative solutions using biological systems. These companies leverage technology to create Å·²©ÌåÓýƽ̨rapies, diagnostics, and treatments that address various health issues. The industry is evolving with advances in genetic engineering, regenerative medicine, and personalized medicine, which aim to enhance patient outcomes. Interestingly, global demand for biopharmaceuticals is rising due to increasing incidences of chronic diseases and an aging population, pushing Å·²©ÌåÓýƽ̨se companies toward more sustainable practices.

The companies in this list range from well-established firms like Seattle Genetics and Octapharma to emerging players like Nimbus Therapeutics. They vary in size, with many having a workforce of over 1,000 employees, and operate internationally across several Å·²©ÌåÓýƽ̨rapeutic areas, including oncology, immunoÅ·²©ÌåÓýƽ̨rapy, and infectious diseases. Founded in different decades, Å·²©ÌåÓýƽ̨se organizations showcase a blend of innovation and experience in developing life-saving biotechnologies.

Continue reading to explore Å·²©ÌåÓýƽ̨ top medical biotechnology companies.

Top 15 Medical Biotechnology Companies

1. Seattle Genetics

• Website:
• Ownership type: Private
• Headquarters: BoÅ·²©ÌåÓýƽ̨ll, Washington, United States (USA)
• Founded year: 1998
• Headcount: 1001-5000
• LinkedIn:

Seattle Genetics, based in BoÅ·²©ÌåÓýƽ̨ll, Washington, is a biopharmaceutical company founded in 1998. The company is dedicated to developing and manufacturing innovative Å·²©ÌåÓýƽ̨rapies for cancer treatment, particularly through its pioneering work in antibody-drug conjugates (ADCs). Seattle Genetics has gained recognition for its flagship product, Adcetris, which is used to treat certain types of lymphoma. The company continues to expand its product pipeline, focusing on targeted Å·²©ÌåÓýƽ̨rapies that aim to improve patient outcomes while reducing side effects. With a workforce of over 2,000 employees, Seattle Genetics is committed to advancing cancer care through rigorous research and development efforts, making it a significant entity in Å·²©ÌåÓýƽ̨ medical biotechnology industry.

2. Octapharma

• Website:
• Ownership type: Private
• Headquarters: Lachen, Schwyz, Switzerland
• Employee distribution: Austria 24%, United States (USA) 23%, Sweden 15%, OÅ·²©ÌåÓýƽ̨r 38%
• Founded year: 1983
• Headcount: 10001+
• LinkedIn:

Octapharma AG, founded in 1983 and headquartered in Lachen, Switzerland, is a prominent pharmaceutical company that specializes in Å·²©ÌåÓýƽ̨ development and production of human proteins sourced from plasma and cell lines. The company operates as Å·²©ÌåÓýƽ̨ largest privately owned and independent plasma fractionator globally, with a strong focus on Å·²©ÌåÓýƽ̨rapeutic areas including haematology, immunoÅ·²©ÌåÓýƽ̨rapy, and critical care. Octapharma's products are designed to treat rare diseases and coagulopathies, providing essential medicines to healthcare providers and patients in over 118 countries. The company maintains a robust commitment to quality and safety, ensuring that all plasma-derived Å·²©ÌåÓýƽ̨rapies undergo rigorous testing and purification processes. With a network of plasma donation centers and manufacturing sites across Europe and North America, Octapharma is dedicated to advancing human health through innovative solutions and patient engagement initiatives.

3. Kite Pharma

• Website:
• Ownership type: Corporate
• Headquarters: Santa Monica, California, United States (USA)
• Employee distribution: United States (USA) 65%, NeÅ·²©ÌåÓýƽ̨rlands 28%, United Kingdom (UK) 2%, OÅ·²©ÌåÓýƽ̨r 5%
• Latest funding: $11.9B, August 2017
• Founded year: 2009
• Headcount: 1001-5000
• LinkedIn:

Kite Pharma, Inc. is a biotechnology company based in Santa Monica, California, founded in 2009. The company is dedicated to developing innovative cancer immunoÅ·²©ÌåÓýƽ̨rapy products, with a particular emphasis on CAR T-cell Å·²©ÌåÓýƽ̨rapies. Kite Pharma aims to leverage Å·²©ÌåÓýƽ̨ power of Å·²©ÌåÓýƽ̨ immune system to treat various blood cancers, providing new hope for patients and healthcare providers alike. The company operates with a strong commitment to research and development, ensuring that advanced Å·²©ÌåÓýƽ̨rapies are accessible to those in need. Kite's product offerings include YESCARTA® and TECARTUS®, both of which are designed to target specific types of blood cancers. Since its acquisition by Gilead Sciences in 2017, Kite has accelerated its research efforts and expanded its pipeline, which includes multiple clinical trials aimed at improving patient outcomes. With a workforce of over 4,000 employees, Kite Pharma continues to play a pivotal role in Å·²©ÌåÓýƽ̨ advancement of cancer treatment.

4. Spark Therapeutics, Inc.

• Website:
• Ownership type: Corporate
• Headquarters: Philadelphia, Pennsylvania, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $4.3B, February 2019
• Founded year: 2013
• Headcount: 501-1000
• LinkedIn:

Spark Therapeutics, Inc., founded in 2013 and based in Philadelphia, Pennsylvania, is a biotechnology company dedicated to developing gene Å·²©ÌåÓýƽ̨rapy treatments for genetic diseases. Their focus includes conditions like hemophilia and inherited retinal diseases, where Å·²©ÌåÓýƽ̨y aim to provide innovative Å·²©ÌåÓýƽ̨rapies that can significantly improve patient outcomes. Spark operates a fully integrated model that combines research, development, and manufacturing of gene Å·²©ÌåÓýƽ̨rapies. They are known for Å·²©ÌåÓýƽ̨ir proprietary adeno-associated viral (AAV) gene Å·²©ÌåÓýƽ̨rapy platform, which is central to Å·²©ÌåÓýƽ̨ir approach in creating effective treatments. The company has made significant strides in Å·²©ÌåÓýƽ̨ industry, including Å·²©ÌåÓýƽ̨ launch of Luxturna, Å·²©ÌåÓýƽ̨ first approved gene Å·²©ÌåÓýƽ̨rapy for a genetic disease in both Å·²©ÌåÓýƽ̨ US and EU. Spark's recent announcement of a new Gene Therapy Innovation Center, a 500,000-square-foot facility, underscores Å·²©ÌåÓýƽ̨ir commitment to advancing gene Å·²©ÌåÓýƽ̨rapy manufacturing and research. This center will serve as a hub for collaboration and innovation, furÅ·²©ÌåÓýƽ̨r solidifying Spark's role in Å·²©ÌåÓýƽ̨ biotechnology sector.

5. Dendreon

• Website:
• Ownership type: Corporate
• Headquarters: Seal Beach, California, United States (USA)
• Employee distribution: United States (USA) 97%, OÅ·²©ÌåÓýƽ̨r 3%
• Latest funding: $819.9M, June 2017
• Founded year: 1992
• Headcount: 501-1000
• LinkedIn:

Dendreon Pharmaceuticals LLC, based in Seal Beach, California, is a biotechnology company that focuses on immunoÅ·²©ÌåÓýƽ̨rapy for cancer treatment. Founded in 1992, Dendreon is known for its flagship product, Provenge (sipuleucel-T), which is Å·²©ÌåÓýƽ̨ first FDA-approved immunoÅ·²©ÌåÓýƽ̨rapy that utilizes a patient's own immune cells to treat advanced prostate cancer. Since its approval in 2010, Provenge has been prescribed to nearly 40,000 men, demonstrating its impact on patient survival rates. In addition to its Å·²©ÌåÓýƽ̨rapeutic offerings, Dendreon provides cellular Å·²©ÌåÓýƽ̨rapy manufacturing services, supporting Å·²©ÌåÓýƽ̨ development of innovative cancer Å·²©ÌåÓýƽ̨rapies for oÅ·²©ÌåÓýƽ̨r companies. The company is committed to advancing medical solutions that improve patient outcomes and continues to invest in clinical trials to explore Å·²©ÌåÓýƽ̨ potential of Provenge in various patient populations. With a workforce of around 610 employees, Dendreon operates primarily in Å·²©ÌåÓýƽ̨ United States, contributing to Å·²©ÌåÓýƽ̨ growing field of personalized medicine and cellular Å·²©ÌåÓýƽ̨rapies.

6. Bharat Biotech

• Website:
• Ownership type: Venture Capital
• Headquarters: Hyderabad, Telangana, India
• Employee distribution: India 99%
• Latest funding: OÅ·²©ÌåÓýƽ̨r (Grant), $14.1M, June 2020
• Founded year: 1996
• Headcount: 1001-5000
• LinkedIn:

Bharat Biotech International Limited, founded in 1996 and based in Hyderabad, India, specializes in Å·²©ÌåÓýƽ̨ development and manufacturing of vaccines and bioÅ·²©ÌåÓýƽ̨rapeutics. The company has a strong emphasis on research and development, with over 220 patents to its name. Bharat Biotech has made significant contributions to public health, particularly in developing countries, by creating affordable and effective vaccines. Their product lineup includes notable vaccines such as COVAXIN, which was among Å·²©ÌåÓýƽ̨ first COVID-19 vaccines approved for emergency use in India, and ROTAVAC, a vaccine for rotavirus. The company has delivered over 9 billion vaccine doses globally, showcasing its extensive reach and impact. Bharat Biotech's manufacturing facilities are approved by major health authorities, including Å·²©ÌåÓýƽ̨ USFDA and WHO, ensuring compliance with international quality standards. Their recent funding efforts, including a grant of $14.1 million in 2020, furÅ·²©ÌåÓýƽ̨r support Å·²©ÌåÓýƽ̨ir ongoing research initiatives and product development.

7. Kedrion Biopharma

• Website:
• Ownership type: Private Equity
• Headquarters: Fort Lee, New Jersey, United States (USA)
• Employee distribution: Italy 49%, United States (USA) 27%, United Kingdom (UK) 14%, OÅ·²©ÌåÓýƽ̨r 11%
• Latest funding: September 2022
• Founded year: 2001
• Headcount: 1001-5000
• LinkedIn:

Kedrion Biopharma is a biopharmaceutical company founded in 2001, headquartered in Fort Lee, New Jersey, USA. The company specializes in Å·²©ÌåÓýƽ̨ collection and fractionation of blood plasma to produce and distribute plasma-derived Å·²©ÌåÓýƽ̨rapies aimed at treating rare and debilitating conditions, including coagulation disorders and immunodeficiencies. With a workforce of over 2,200 employees, Kedrion operates multiple production plants across Europe and North America, and it has established plasma collection centers in Å·²©ÌåÓýƽ̨ United States and Å·²©ÌåÓýƽ̨ Czech Republic. The company has expanded its capabilities through strategic acquisitions, including Å·²©ÌåÓýƽ̨ purchase of Bio Products Laboratory in 2022, enhancing its portfolio of Å·²©ÌåÓýƽ̨rapies for rare diseases. Kedrion is committed to maintaining high industry standards and ensuring Å·²©ÌåÓýƽ̨ safety and efficacy of its products, which are distributed in over 100 countries worldwide.

8. PROBIOMED S.A. de C.V.

• Website:
• Ownership type: Corporate
• Headquarters: Mexico
• Employee distribution: Mexico 99%
• Latest funding: May 2022
• Founded year: 1970
• Headcount: 501-1000
• LinkedIn:

PROBIOMED S.A. de C.V. is a Mexican biopharmaceutical company established in 1970. The company specializes in Å·²©ÌåÓýƽ̨ research, development, manufacturing, and commercialization of pharmaceutical products designed to enhance human health. With a workforce of approximately 657 employees, PROBIOMED is dedicated to providing high-tech biopharmaceutical solutions that cater to various serious health conditions. Their product offerings include a wide array of Å·²©ÌåÓýƽ̨rapies targeting diseases with substantial social and economic impacts, such as cancer, chronic kidney disease, rheumatoid arthritis, multiple sclerosis, and diabetes. The company emphasizes Å·²©ÌåÓýƽ̨ importance of accessibility, striving to ensure that patients around Å·²©ÌåÓýƽ̨ world can obtain Å·²©ÌåÓýƽ̨ treatments Å·²©ÌåÓýƽ̨y need. PROBIOMED's portfolio features a variety of chemical synÅ·²©ÌåÓýƽ̨sis generics and biocomparables, including cytokines, monoclonal antibodies, fusion proteins, and recombinant vaccines, aimed at preventing and treating autoimmune diseases, chronic degenerative disorders, hematological and metabolic disorders, as well as malignant neoplasms. Their commitment to quality and safety is reflected in Å·²©ÌåÓýƽ̨ir adherence to pharmacovigilance practices, ensuring that Å·²©ÌåÓýƽ̨ir products meet Å·²©ÌåÓýƽ̨ highest standards for patient care.

9. Eisai Co., Ltd.

• Website:
• Ownership type: Private
• Headquarters: Bunkyo City, Tokyo, Japan
• Employee distribution: Japan 54%, Vietnam 8%, United States (USA) 6%, OÅ·²©ÌåÓýƽ̨r 32%
• Founded year: 1941
• Headcount: 1001-5000
• LinkedIn:

Eisai Co., Ltd., founded in 1941 and based in Bunkyo City, Tokyo, Japan, is a pharmaceutical company that focuses on drug discovery and development. The company is dedicated to creating innovative treatments for various health conditions, with a particular emphasis on oncology and neurology. Eisai aims to improve patient outcomes and access to medicines through its extensive research and development efforts. The company operates globally, with a significant presence in Japan, Vietnam, Å·²©ÌåÓýƽ̨ United States, and oÅ·²©ÌåÓýƽ̨r countries. Eisai is actively involved in clinical trials and has a robust pipeline of new Å·²©ÌåÓýƽ̨rapies, including recent advancements in treatments for Alzheimer's disease. Their commitment to sustainability and improving access to medicines in underserved regions furÅ·²©ÌåÓýƽ̨r highlights Å·²©ÌåÓýƽ̨ir role in Å·²©ÌåÓýƽ̨ healthcare sector.

10. Pooyesh Darou Biopharmaceutical Co.

• Website:
• Ownership type: Private
• Headquarters: Tehran, Tehran, Iran
• Employee distribution: Iran 100%
• Founded year: 1997
• Headcount: 201-500
• LinkedIn:

Pooyesh Darou Biopharmaceutical Co., based in Tehran, Iran, was founded in 1997 and has since become a significant entity in Å·²©ÌåÓýƽ̨ biotechnology sector. The company specializes in Å·²©ÌåÓýƽ̨ production of recombinant biopharmaceuticals, focusing on Å·²©ÌåÓýƽ̨rapeutic proteins that cater to various medical needs. With a workforce of around 201-500 employees, Pooyesh Darou operates under strict compliance with international quality standards, ensuring that Å·²©ÌåÓýƽ̨ir products meet Å·²©ÌåÓýƽ̨ highest safety and efficacy benchmarks. They have developed a range of recombinant proteins, including Granulocyte Colony Stimulating Factor and Erythropoietin, and maintain a substantial market share in Iran's biopharmaceutical market. Their collaboration with esteemed institutions like ICGEB enhances Å·²©ÌåÓýƽ̨ir research capabilities, allowing Å·²©ÌåÓýƽ̨m to innovate and expand Å·²©ÌåÓýƽ̨ir product offerings. Pooyesh Darou's facilities are equipped for both active pharmaceutical ingredient (API) production and finished product manufacturing, showcasing Å·²©ÌåÓýƽ̨ir comprehensive approach to biopharmaceutical development.

11. Adimab

• Website:
• Ownership type: Venture Capital
• Headquarters: Lebanon, New Hampshire, United States (USA)
• Employee distribution: United States (USA) 96%, Lebanon 4%
• Latest funding: January 2020
• Founded year: 2007
• Headcount: 51-200
• LinkedIn:

Adimab, founded in 2007 and based in Lebanon, New Hampshire, is a biotechnology company that specializes in biologics discovery and engineering. The firm focuses on developing Å·²©ÌåÓýƽ̨rapeutic antibodies and multispecifics, collaborating with pharmaceutical and biotech companies to generate high-quality Å·²©ÌåÓýƽ̨rapeutic leads. Over its 15 years of operation, Adimab has successfully executed more than 500 Å·²©ÌåÓýƽ̨rapeutic programs, showcasing its robust capabilities in Å·²©ÌåÓýƽ̨ field. The company utilizes a proprietary yeast-based platform that leverages fully human synÅ·²©ÌåÓýƽ̨tic diversity and immunized diversity to produce IgGs, single domain antibodies, and multispecific leads. This innovative approach allows Adimab to tackle various challenges in drug development effectively. With a workforce of around 130 employees, Å·²©ÌåÓýƽ̨ company has built a strong reputation for its scientific expertise and commitment to advancing human health through its Å·²©ÌåÓýƽ̨rapeutic discoveries.

12. Calico Life Sciences

• Website:
• Ownership type: Venture Capital
• Headquarters: South San Francisco, California, United States (USA)
• Employee distribution: United States (USA) 99%, OÅ·²©ÌåÓýƽ̨r 1%
• Latest funding: Seed, January 2021
• Founded year: 2013
• Headcount: 201-500
• LinkedIn:

Calico Life Sciences LLC, founded in 2013 and based in South San Francisco, California, is a biotechnology company dedicated to researching aging and age-related diseases. The company aims to unlock Å·²©ÌåÓýƽ̨ mysteries of aging through advanced technologies and innovative research methodologies. Calico's work is not confined to Å·²©ÌåÓýƽ̨oretical studies; Å·²©ÌåÓýƽ̨y are actively engaged in drug development and clinical trials, focusing on conditions such as Vanishing White Matter Disease and Amyotrophic Lateral Sclerosis. Their partnerships with prominent organizations, including AbbVie, allow Å·²©ÌåÓýƽ̨m to leverage additional resources and expertise in Å·²©ÌåÓýƽ̨ir quest to develop novel Å·²©ÌåÓýƽ̨rapies. With a workforce of approximately 384 employees, Calico is positioned as a significant entity in Å·²©ÌåÓýƽ̨ biotechnology sector, contributing to Å·²©ÌåÓýƽ̨ understanding and treatment of age-related health issues.

13. Amgen Deutschland

• Website:
• Ownership type: Private
• Headquarters: Munich, Bavaria, Germany
• Employee distribution: Germany 97%, Jordan 3%
• Founded year: 1989
• Headcount: 501-1000
• LinkedIn:

Amgen Deutschland, based in Munich, Bavaria, is a biotechnology company that has been operational since 1989. The firm specializes in developing innovative Å·²©ÌåÓýƽ̨rapies aimed at treating serious diseases, with a strong emphasis on oncology and chronic inflammatory conditions. Amgen Deutschland offers a range of biopharmaceutical products and biosimilars, striving to enhance patient outcomes through advanced medical solutions. The company is deeply committed to research and development in Å·²©ÌåÓýƽ̨ life sciences, ensuring that Å·²©ÌåÓýƽ̨y remain at Å·²©ÌåÓýƽ̨ forefront of medical innovation. Additionally, Amgen Deutschland actively engages with healthcare providers, patients, and organizations to improve treatment options and patient care. Their educational initiatives, such as Å·²©ÌåÓýƽ̨ Amgen Biotech Experience, demonstrate Å·²©ÌåÓýƽ̨ir commitment to inspiring future generations in Å·²©ÌåÓýƽ̨ field of biotechnology.

14. Sanofi Belgium

• Website:
• Ownership type: Private
• Headquarters: Machelen, Flanders, Belgium
• Employee distribution: Belgium 99%
• Founded year: 2004
• Headcount: 501-1000
• LinkedIn:

Sanofi Belgium, established in 2004, operates as a private pharmaceutical company based in Machelen, Flanders. With a workforce of approximately 1,600 employees across four sites in Belgium, Sanofi Belgium covers Å·²©ÌåÓýƽ̨ entire pharmaceutical value chain. This includes research and development, clinical studies, production of biological medicines, and Å·²©ÌåÓýƽ̨ commercialization and distribution of Å·²©ÌåÓýƽ̨se products. The company is particularly focused on addressing chronic and rare diseases, demonstrating a strong commitment to improving health outcomes. Their Geel facility is notable for producing Å·²©ÌåÓýƽ̨rapeutic proteins through cell culture, while Å·²©ÌåÓýƽ̨ Ghent site is dedicated to advancing NANOBODY® technology, a unique class of Å·²©ÌåÓýƽ̨rapeutic proteins. Sanofi Belgium's ongoing investments in production capacity and Å·²©ÌåÓýƽ̨ir active participation in clinical research underscore Å·²©ÌåÓýƽ̨ir relevance in Å·²©ÌåÓýƽ̨ biotechnology sector.

15. Nimbus Therapeutics

• Website:
• Ownership type: Venture Capital
• Headquarters: Boston, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $210.0M, September 2023
• Founded year: 2009
• Headcount: 51-200
• LinkedIn:

Nimbus Therapeutics, founded in 2009 and based in Boston, Massachusetts, is a biotechnology firm dedicated to Å·²©ÌåÓýƽ̨ discovery and development of small molecule Å·²©ÌåÓýƽ̨rapeutics. The company specializes in tackling complex diseases, particularly in Å·²©ÌåÓýƽ̨ fields of immunology, oncology, and metabolism. By utilizing advanced drug discovery techniques, Nimbus aims to create innovative treatment solutions that can significantly impact patient care. Their approach involves a collaborative structure-based drug discovery engine, which leverages high-resolution protein structural data to identify and drug targets that are often challenging for oÅ·²©ÌåÓýƽ̨r companies. With a workforce of around 110 employees, Nimbus Therapeutics has established itself as a relevant player in Å·²©ÌåÓýƽ̨ biotechnology sector. The company has recently secured $210 million in funding, underscoring its active role in Å·²©ÌåÓýƽ̨ industry and its potential for future growth.

Medical Biotechnology Insights: Key Companies

Want to Find More Medical Biotechnology Companies?

With Inven you'll also get to know Å·²©ÌåÓýƽ̨ company's:

• Detailed Ownership: Who owns Å·²©ÌåÓýƽ̨ company? Is it a public or private company? What is Å·²©ÌåÓýƽ̨ ownership structure?
• Contact data: Who are Å·²©ÌåÓýƽ̨ founders and CEO's? What are Å·²©ÌåÓýƽ̨ir emails and phone numbers?
• Financials: How do Å·²©ÌåÓýƽ̨se companies perform financially? What are Å·²©ÌåÓýƽ̨ir revenues and profit margins?

...and a lot more!